September 2024 Letter to Shareholders - CytoDyn Inc.
CytoDyn Inc. updates shareholders on significant progress, including FDA approval, clinical trials, and partnerships, focusing on leronlimab's potential in oncology, inflammation, and other therapeutic areas.
Reference News
CytoDyn Inc. updates shareholders on significant progress, including FDA approval, clinical trials, and partnerships, focusing on leronlimab's potential in oncology, inflammation, and other therapeutic areas.
CytoDyn Inc. (CYDY) reports significant 2024 progress, including FDA lifting leronlimab's clinical hold, submitting two trial protocols, settling with Amarex for $10 million, and initiating pre-clinical/clinical trials. Focus areas include oncology (colorectal cancer, triple-negative breast cancer, glioblastoma) and inflammation (HIV-related chronic inflammation, Alzheimer's Disease, chronic fatigue syndrome). The company believes it has sufficient cash to advance development into 2025.